Regeneron Pharmaceuticals is seeing notable gains in its stock price following significant developments in its business strategy.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is rising today, up by 1.18% to close at CA$747.42. This positive movement comes on the heels of recent announcements regarding the expansion of its partnership with Sanofi and promising new clinical data.
Investor takeaway: Investors are encouraged by the expanded collaboration with Sanofi, which could enhance Regeneron's pipeline and revenue potential, despite some near-term earnings headwinds.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$74.79B
P/E
18.0x
Div. yield
0.50%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
-1.57%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 5, 2026
Wall Street analysts forecast REGN stock price to rise 15.5% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$853.19
+15.5% Upside
Previously C$850.88 on Sep 25, 2026
Current Price
C$738.72
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.7%
Annualized
90-Day Vol
29.8%
Annualized
Trend (90d)
+45.9%
Annualized drift
90d Mean
C$870.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$780.17 | C$706.58 – C$861.41 |
| 60 trading days | C$823.94 | C$716.22 – C$947.85 |
| 90 trading days | C$870.16 | C$732.96 – C$1033.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.18% Increase in Stock Price
Regeneron's stock price has increased by 1.18%, reflecting investor optimism following significant strategic developments.
Bull case
The expanded alliance with Sanofi, valued at up to $8 billion and including $1 billion upfront, points to strong future revenue opportunities through the development of long-acting immunology therapies. Additionally, new clinical data in oncology and obesity programs could diversify and strengthen Regeneron's earnings mix.
Bear case
Despite the positive news, Regeneron faces challenges. Analysts project an earnings headwind of about $0.18 per share in Q3 due to R&D-related charges. There are also legal risks from past trials that could affect investor sentiment.
Expanded Sanofi Alliance
Advertisement
Regeneron recently announced an expansion of its long-standing collaboration with Sanofi, which includes an upfront payment of $1 billion and potential future milestone payments of up to $7 billion. This partnership aims to develop four next-generation long-acting immunology therapies, strengthening Regeneron's pipeline and revenue prospects.
New Clinical Data Presentation
At the recent European Society for Medical Oncology (ESMO) Congress, Regeneron showcased promising new clinical data across various oncology programs. This includes advancements in treatments for cutaneous squamous cell carcinoma and insights into cancer-associated complications, further solidifying Regeneron's commitment to addressing complex health challenges.
Market Reaction and Future Outlook
The stock's rise reflects investor confidence in Regeneron's strategic direction and potential for growth. However, analysts caution about the earnings headwinds expected in Q3 due to R&D charges and ongoing legal risks. Investors are advised to monitor these developments closely as they could impact future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
